Contact CFFC

Jul

Clinical Trial Alerts – July 2022

The cystic Fibrosis Foundation issued the following clinical trial alerts in July.

July 6, 2022

SHIP CT: Study of hypertonic saline in preschoolers

Status: Completed with Results

Description: This study took place in Europe, Australia and the U.S. It evaluated the safety and effectiveness of hypertonic saline compared to isotonic saline (normal saline) in preschool children with CF.

Age: 3 Years to 5 Years

Mutation: No Mutation Requirement

Fev1% Predicted: No FEV1 Limit

Number of Visits: 6

Length of Participation: 54 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02950883

Phase 2 study of CTX-4430 in people with CF (EMPIRE)

Status: Completed with Results

Description: This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat)This study evaluated the safety and effectiveness of the anti-inflammatory drug CTX-4430 (acebilustat).

Age: 18 Years to 30 Years

Mutation: No Mutation Requirement

Fev1% Predicted: 50% or greater

Number of Visits: 15

Length of Participation: 1 years

ClinicalTrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT02443688

Study of ELX-02 in adults with cystic fibrosis who have at least one nonsense mutation

Status: Enrolling

Description: This study will look at the safety and tolerability of ELX-02 and how the body processes the drug, a molecule intended to restore CFTR function. Multiple doses of ELX-02 will be tested in adults with cystic fibrosis who have at least one G542X or similar nonsense mutation.

Age: 18 Years and Older

Mutation: No Copies F508del

Fev1% Predicted: 40% or greater

Number of Visits: 8

Length of Participation: 9 weeks

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT04135495


Comments are closed.